<DOC>
	<DOCNO>NCT00240591</DOCNO>
	<brief_summary>This study long-term follow-up patient complete least two year follow-up treatment Tositumomab and/or Iodine I 131 Tositumomab ( BEXXAR ) Study RIT-I-000 , RIT-II-001 , RIT-II-002 , RIT-II-004 CP-97-012 . All patient assess survival disease status , include subsequent therapy NHL , long term safety . Laboratory evaluation consist TSH level ( patient ) complete blood cell ( CBC ) count differential platelet count ( patient continue response ) obtain annually Year 10 post treatment Tositumomab and/or Iodine I 131 Tositumomab . Patients remain response previous treatment BEXXAR , additionally follow radiographically response progression .</brief_summary>
	<brief_title>Patients With Low-Grade Non-Hodgkin 's Lymphoma Previously Treated With Tositumomab and/or Iodine I 131 Tositumomab</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Iodine-131 anti-B1 antibody</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Iodine</mesh_term>
	<criteria>Patients must enrol one follow Corixa sponsor clinical trial : RITI000 , RITII001 , RITII002 , RIT II004 CP97012 &gt; 2 year post Tositumomab and/or Iodine I 131 Tositumomab administration . Patients must give write informed consent sign IRB/ethics committee approve consent form prior entry followup study . Inability meet reference inclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>BEXXAR</keyword>
	<keyword>Tositumomab</keyword>
	<keyword>Iodine I 131 Tositumomab</keyword>
	<keyword>low-grade follicular lymphoma</keyword>
</DOC>